TY - JOUR
T1 - Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection
AU - Vohra, Manik
AU - Sharma, Anu Radha
AU - Satyamoorthy, Kapaettu
AU - Rai, Padmalatha S.
N1 - Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Immunomodulatory and analgesic effects of dexamethasone are clinically well established, and this synthetic corticosteroid acts as an agonist of glucocorticoid receptors. Early results of the RECOVERY Trial from the United Kingdom and others suggest certain benefits of dexamethasone against COVID-19 chronic patients. The efforts have been acknowledged by World Health Organization with an interim guideline to use in patients with a severe and critical illness. The inherent genetic variations in genes such as CYP3A5, NR3C1, NR3C2, etc., involved in the pharmacokinetic and pharmacodynamic processes may influence dexamethasone's effects as an anti-inflammatory drug. Besides, the drug may influence transcriptome or metabolic changes in the individuals. In the present review, we summarize the reported genetic variations that impact dexamethasone response and discuss dexamethasone-induced changes in transcriptome and metabolome that may influence potential treatment outcome against COVID-19.
AB - Immunomodulatory and analgesic effects of dexamethasone are clinically well established, and this synthetic corticosteroid acts as an agonist of glucocorticoid receptors. Early results of the RECOVERY Trial from the United Kingdom and others suggest certain benefits of dexamethasone against COVID-19 chronic patients. The efforts have been acknowledged by World Health Organization with an interim guideline to use in patients with a severe and critical illness. The inherent genetic variations in genes such as CYP3A5, NR3C1, NR3C2, etc., involved in the pharmacokinetic and pharmacodynamic processes may influence dexamethasone's effects as an anti-inflammatory drug. Besides, the drug may influence transcriptome or metabolic changes in the individuals. In the present review, we summarize the reported genetic variations that impact dexamethasone response and discuss dexamethasone-induced changes in transcriptome and metabolome that may influence potential treatment outcome against COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85108206451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108206451&partnerID=8YFLogxK
U2 - 10.2217/pme-2020-0183
DO - 10.2217/pme-2020-0183
M3 - Article
C2 - 34086487
AN - SCOPUS:85108206451
SN - 1741-0541
VL - 18
SP - 389
EP - 398
JO - Personalized Medicine
JF - Personalized Medicine
IS - 4
ER -